Cisplatin-gemcitabine-vinorelbine (PGV) vs cisplatin-vinorelbine (PV) vs cisplatin-gemcitabine (PG) in advanced non-small cell lung cancer (NSCLC). Interim analysis of a SICOG phase III trial

P. Comella, G. Comella(Tumour Institute of Tuscany), G.P. Nicolella(Radiation Oncology Institute), N. Panza, R Cioffi(Medical Center Hospital), Luigi Maiorino(Medical Center Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, V. Lorusso(Gastroenterology Hospital "Saverio de Bellis"), Giuseppe DeCataldis
European Journal of Cancer
September 1, 1999
10.1016/s0959-8049(99)81397-5
Cited by 3

Related Papers

Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Lapatinib in breast cancer
|Annals of Oncology|2007|129
Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|1999|73
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
|Journal of Clinical Oncology|2018|70